 |
|
|
|
 |
|
|
| Article 1 to 10 out of 32 concerning Intercell AG
|
-
IOMAI shareholders approve acquisition by Intercell
(06 Aug 2008)
Iomai shareholders voted in favour of the acquisition at the special shareholder meeting
Intercell AG announced that the acquisition of Iomai by Intercell has been approved by the shareholders of Iomai in a special meeting which was held at Iomai's offices in Gaithersburg, MD. The merger was approved by 99,97 % of the votes cast - ...
-
Intercell: IOMAI Acquisition granted clearance by US Authorities
(15 Jul 2008)
Intercell AG announced that, following review by the United States Securities and Exchange Commission (SEC), Iomai Corporation filed a definitive proxy statement on July 10, 2008 for Iomai stockholders regarding the proposed acquisition by Intercell ...
-
Intercell receives milestone payment triggered by initiation of further clinical trial for Flu vaccine with IC31
(16 Jun 2008)
Further clinical trial for a seasonal flu vaccine containing Intercell's adjuvant IC31 being initiated
Intercell AG announced progress in its collaboration with Novartis to develop an improved Influenza vaccine. Novartis now has initiated its in-house development program with clinical trials designed to demonstrate safety and immunogenicity of a ...
-
Intercell AG to acquire Iomai Corporation to expand late stage product pipeline and strengthen leadership in vaccine innovation
(14 May 2008)
Intercell AG and Iomai Corporation announced that they have entered into a definitive agreement pursuant to which Intercell will acquire Iomai for USD 6.60 per share representing a fully diluted equity value of approximately USD 189 million (EUR 122 ...
-
Intercell receives The Vaccine Industry Excellence Award
(28 Apr 2008)
Intercells Hepatitis C vaccine candidate was awarded in the category of Best New Therapeutic Vaccine at the World Vaccine Congress
In the course of the World Vaccine Congress in Washington D.C., USA, Intercell was awarded The Vaccine Industry Excellence Award in the category Best New Therapeutic Vaccine for its therapeutic Hepatitis C (HCV) vaccine candidate. Earlier this year, ...
-
Intercell and its partner institutions are awarded an EU grant for targeting research and novel treatments of fungal infections
(24 Apr 2008)
Intercell further strengthens its fungal franchise by supporting the new Christian Doppler Laboratory
Intercell AG announced that the joint project to develop protective treatments against fungal infections was awarded an EUgrant. Intercell is coordinating a European consortium of three academic and commercial partners within the "CanVac" project. ...
-
Intercells investigational vaccine against Japanese Encephalitis shows excellent safety and immunogenicity in Phase II trials
(18 Apr 2008)
Japanese Encephalitis (JE) Vaccine meets primary endpoints in Phase II trials in children
Intercell AG and its partner Biological E. Ltd. announced the analysis of Phase II data for its investigational pediatric vaccine against Japanese Encephalitis. The randomized and controlled study shows an excellent safety and immunogenicity profile ...
-
Intercell: Licensure application for Japanese Encephalitis vaccine submitted to Therapeutic Goods Administration in Australia
(04 Mar 2008)
Intercell AG announced the submission of application to register Intercells investigational Japanese Encephalitis vaccine in Australia to the Therapeutic Goods Administration (TGA). The submission process was executed by Intercells partner CSL ...
-
Intercell completes Phase I clinical trial for an improved seasonal Influenza vaccine formulated with IC31
(29 Feb 2008)
Intercell's strategic Flu partner Novartis to include IC31® in further clinical trials
Intercell AG announced the completion of Phase I clinical trials of the companys adjuvant IC31® in combination with the seasonal, trivalent influenza vaccine Agrippal® from Novartis.In this randomized, controlled Phase I trial, 72 individuals ...
-
Vaccine formulated with Intercells adjuvant IC31 part of a broader collaboration to fight Tuberculosis
(18 Feb 2008)
Intercell AG announced that a Tuberculosis vaccine, which is currently tested in clinical trials and which contains antigens discovered by Statens Serum Institut formulated with Intercells adjuvant IC31®, will be further developed in a partnership ...
Additional information
Intercell AG
Wien, Austria
Company
|
|
|
|
|
|
Top
